Cover Image
市場調查報告書

日光角化症:開發中產品分析

Actinic (Solar) Keratosis - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 192432
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
日光角化症:開發中產品分析 Actinic (Solar) Keratosis - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 75 Pages
簡介

日光性角化症(actinic keratosis)又稱光化性角化症,是會造成鱗狀或硬皮的皮膚病變。最常見的是沒有頭髮的頭皮、臉、耳朵、嘴唇、手背、前膊後部、肩膀、脖子及其他頻繁受陽光曝曬的部位。症狀有硬化、疣狀表皮、斑點、皮膚最上層的瘤、患部發癢或刺癢感,顏色為粉色、發紅、茶色或膚色等。因素有年齡,長年曝曬陽光的氣候,暴露在非常強烈的日光和曬黑的頻率,青白色皮膚,紅·金髮,青·淡色的瞳孔,化療的結果造成的免疫系統衰弱,慢性白血病,愛滋病,器官移植的投藥等。

本報告提供日光角化症的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

日光角化症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

日光角化症:企業開發中的治療藥

日光角化症:大學/機關研究中的治療藥

日光角化症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

日光角化症:企業開發中的產品

日光角化症:大學/機關研究中的產品

日光角化症的治療藥的開發企業

  • 3M Drug Delivery Systems
  • Advancell
  • Biofrontera AG
  • Clinuvel Pharmaceuticals Limited
  • Digna Biotech, S.L.
  • Dolorgiet Gmbh & Co. Kg
  • Foamix Pharmaceuticals Ltd.
  • G&E Herbal Biotechnology Co., Ltd.
  • Galderma S.A.
  • Kinex Pharmaceuticals, LLC
  • LEO Pharma A/S
  • Novartis AG
  • Novelix Pharmaceuticals, Inc.
  • Promius Pharma, LLC
  • Spherium Biomed S.L.

日光角化症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • 854-A
  • ACT-01
  • AD-17137
  • AK-3012
  • 胺基乙醯丙酸鹽酸鹽
  • ANs-40
  • ANS-401
  • ANS-403
  • CUV-9900
  • DFD-07
  • DFD-08
  • disitertide
  • imiquimod
  • KX-01
  • LEO-43204
  • LFX-453
  • NVX-207
  • 皮膚疾病·免疫疾病·癌症基因重組胜肽
  • reshikimodo
  • 活化皮膚疾病及癌症用蛋白激酶C的小分子
  • SP-12054
  • SRT-100
  • surindaku + 過氧化氫
  • VPE-001

日光角化症:最近的開發平台趨勢

日光角化症:暫停中的計劃

日光角化症:開發中止的產品

日光角化症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8452IDB

Summary

Global Markets Direct's, 'Actinic (Solar) Keratosis - Pipeline Review, H2 2016', provides an overview of the Actinic (Solar) Keratosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Actinic (Solar) Keratosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Actinic (Solar) Keratosis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Actinic (Solar) Keratosis
  • The report reviews pipeline therapeutics for Actinic (Solar) Keratosis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Actinic (Solar) Keratosis therapeutics and enlists all their major and minor projects
  • The report assesses Actinic (Solar) Keratosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Actinic (Solar) Keratosis

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Actinic (Solar) Keratosis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Actinic (Solar) Keratosis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Actinic (Solar) Keratosis Overview
  • Therapeutics Development
    • Pipeline Products for Actinic (Solar) Keratosis - Overview
    • Pipeline Products for Actinic (Solar) Keratosis - Comparative Analysis
  • Actinic (Solar) Keratosis - Therapeutics under Development by Companies
  • Actinic (Solar) Keratosis - Therapeutics under Investigation by Universities/Institutes
  • Actinic (Solar) Keratosis - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Actinic (Solar) Keratosis - Products under Development by Companies
  • Actinic (Solar) Keratosis - Products under Investigation by Universities/Institutes
  • Actinic (Solar) Keratosis - Companies Involved in Therapeutics Development
    • 3M Drug Delivery Systems
    • Athenex, Inc.
    • Digna Biotech, S.L.
    • Foamix Pharmaceuticals Ltd.
    • G&E Herbal Biotechnology Co., Ltd.
    • Galderma S.A.
    • Laboratories Ojer Pharma S.L.
    • LEO Pharma A/S
    • Novartis AG
    • Oncology Research International Limited
    • Promius Pharma, LLC
    • Spherium Biomed S.L.
    • Valeant Pharmaceuticals International, Inc.
    • Vectura Group Plc
  • Actinic (Solar) Keratosis - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • 854-A - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ACT-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AD-17137 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • celecoxib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DFD-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • disitertide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • hydrogen peroxide + sulindac - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IDP-125 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IDP-128 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiquimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiquimod SR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KX-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LEO-43204 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LFX-453 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ORIL-007 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Peptide for Dermatology, Immunology and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • resiquimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKP-024 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Activate Protein Kinase C for Actinic Keratosis and Non-melanoma Skin Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SP-12054 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SRT-100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VDA-1102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VPE-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Actinic (Solar) Keratosis - Dormant Projects
  • Actinic (Solar) Keratosis - Discontinued Products
  • Actinic (Solar) Keratosis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 20, 2015: Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Actinic (Solar) Keratosis, H2 2016
  • Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Actinic (Solar) Keratosis - Pipeline by 3M Drug Delivery Systems, H2 2016
  • Actinic (Solar) Keratosis - Pipeline by Athenex, Inc., H2 2016
  • Actinic (Solar) Keratosis - Pipeline by Digna Biotech, S.L., H2 2016
  • Actinic (Solar) Keratosis - Pipeline by Foamix Pharmaceuticals Ltd., H2 2016
  • Actinic (Solar) Keratosis - Pipeline by G&E Herbal Biotechnology Co., Ltd., H2 2016
  • Actinic (Solar) Keratosis - Pipeline by Galderma S.A., H2 2016
  • Actinic (Solar) Keratosis - Pipeline by Laboratories Ojer Pharma S.L., H2 2016
  • Actinic (Solar) Keratosis - Pipeline by LEO Pharma A/S, H2 2016
  • Actinic (Solar) Keratosis - Pipeline by Novartis AG, H2 2016
  • Actinic (Solar) Keratosis - Pipeline by Oncology Research International Limited, H2 2016
  • Actinic (Solar) Keratosis - Pipeline by Promius Pharma, LLC, H2 2016
  • Actinic (Solar) Keratosis - Pipeline by Spherium Biomed S.L., H2 2016
  • Actinic (Solar) Keratosis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2016
  • Actinic (Solar) Keratosis - Pipeline by Vectura Group Plc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Actinic (Solar) Keratosis - Dormant Projects, H2 2016
  • Actinic (Solar) Keratosis - Dormant Projects (Contd..1), H2 2016
  • Actinic (Solar) Keratosis - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Actinic (Solar) Keratosis, H2 2016
  • Number of Products under Development for Actinic (Solar) Keratosis - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top